Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764083 · ClinicalTrials.gov registry record
Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)
A clinical trial of COVID-19 and SARS-CoV-2, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 2,824
- Enrollment target
- 1
- Study location
NCT05764083: Completed study of COVID-19 and SARS-CoV-2, sponsored by VA Office of Research and Development.
NCT05764083 is a study of COVID-19 and SARS-CoV-2 that has completed, run by VA Office of Research and Development. The registered enrollment target is 2,824 participants, below the 38,455-participant average among 298 other COVID-19 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05764083, a study of COVID-19 and SARS-CoV-2, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 2,824 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to gather information to answer questions about the Coronavirus Disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. This study will collect information and biological specimens from participants who have been tested for the SARS-CoV-2 infection. By doing this study, the investigators hope to learn important new information about SARS-CoV-2 infections and the potentially severe outcomes of COVID-19 to find better ways to manage and treat it in the future. The investigators also hope to learn what makes some people more susceptible to infection to help better inform Veterans on how to reduce their risk of infection. This study also involves the development and maintenance of a participant registry, a data repository, and a biorepository for future research.
Primary Outcome
Mortality
Conditions Studied
Study Locations (1)
California
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,824 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2024-09-30 |
What the finished NCT05764083 record still lists
NCT05764083 is an observational study that tracks outcomes without assigning an intervention. Its 2,824 participants enrollment target places it among the larger protocols in the corpus, below the 38,455-participant average among 298 other COVID-19 trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT05764083 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05764083 about?
NCT05764083 is a clinical study titled "Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)". The purpose of this research is to gather information to answer questions about the Coronavirus Disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. This study will collect information and biological specimens from participants who ha...
What is the current status of trial NCT05764083?
This trial is currently completed. The enrollment target is 2,824 participants. The study started on 2020-07-22. Estimated completion is 2024-09-30.
What conditions does trial NCT05764083 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.
Who is sponsoring clinical trial NCT05764083?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05764083 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05764083's enrollment target sits among peer trials
2,824 38th of 298 higher than 261 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02273297 · 2,821 participants
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
- NCT05932602 · 2,812 participants
AVEIR DR Coverage With Evidence Development (CED) Study
- NCT06150781 · 2,842 participants
Aimovig Pregnancy Exposure Registry
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI